SG10201805674YA - Determinants of cancer response to immunotherapy - Google Patents

Determinants of cancer response to immunotherapy

Info

Publication number
SG10201805674YA
SG10201805674YA SG10201805674YA SG10201805674YA SG10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA SG 10201805674Y A SG10201805674Y A SG 10201805674YA
Authority
SG
Singapore
Prior art keywords
immunotherapy
cancer
determinants
response
neoepitopes
Prior art date
Application number
SG10201805674YA
Inventor
Timothy Chan
Jedd Wolchok
Charen Alexandra Snyder
Vladimir Makarov
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of SG10201805674YA publication Critical patent/SG10201805674YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy. The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy can be predicted. The present invention further comprises the discovery that cancer cells may harbor somatic mutations that result in neoepitopes that are recognizable by a patient's immune system as non-self. The identification of one or more neoepitopes in a cancer sample is useful for determining which cancer patients are likely to respond favorably to immunotherapy, in particular, treatment with an immune checkpoint modulator. [FIG. 1]
SG10201805674YA 2014-01-02 2014-12-23 Determinants of cancer response to immunotherapy SG10201805674YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923183P 2014-01-02 2014-01-02
US201462066034P 2014-10-20 2014-10-20
US201462072893P 2014-10-30 2014-10-30

Publications (1)

Publication Number Publication Date
SG10201805674YA true SG10201805674YA (en) 2018-08-30

Family

ID=53494217

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201805674YA SG10201805674YA (en) 2014-01-02 2014-12-23 Determinants of cancer response to immunotherapy
SG11201605432RA SG11201605432RA (en) 2014-01-02 2014-12-23 Determinants of cancer response to immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201605432RA SG11201605432RA (en) 2014-01-02 2014-12-23 Determinants of cancer response to immunotherapy

Country Status (15)

Country Link
US (1) US20160326597A1 (en)
EP (1) EP3090066A4 (en)
JP (1) JP2017504324A (en)
KR (1) KR20160102314A (en)
CN (1) CN106164289A (en)
AU (1) AU2014374020A1 (en)
BR (1) BR112016015399A2 (en)
CA (1) CA2935214A1 (en)
CL (1) CL2016001708A1 (en)
MX (1) MX2016008771A (en)
PE (1) PE20161344A1 (en)
PH (1) PH12016501329A1 (en)
RU (1) RU2707530C2 (en)
SG (2) SG10201805674YA (en)
WO (1) WO2015103037A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2017537087A (en) 2014-11-13 2017-12-14 ザ ジョンズ ホプキンス ユニバーシティー Checkpoint interruption and microsatellite instability
MA40737A (en) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CA2987730C (en) 2015-04-08 2020-02-18 Nantomics, Llc Cancer neoepitopes
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3362929B1 (en) * 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
EP3362930A4 (en) * 2015-10-12 2019-06-19 Nantomics, LLC Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
IL258688B2 (en) * 2015-10-12 2023-04-01 Nantomics Llc Compositions and methods for viral cancer neoepitopes
WO2017070581A1 (en) * 2015-10-23 2017-04-27 Novartis Ag Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
TWI733719B (en) 2015-12-07 2021-07-21 美商河谷控股Ip有限責任公司 Improved compositions and methods for viral delivery of neoepitopes and uses thereof
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Neoantigen identification, manufacture, and use
CN108472350A (en) * 2016-01-08 2018-08-31 瓦西博迪公司 New epitope RNA cancer vaccines
EP3417289B1 (en) 2016-02-19 2020-12-23 Nant Holdings IP, LLC Methods of immunogenic modulation
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
CA3015528A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3431595A4 (en) * 2016-03-15 2019-11-20 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
RU2769314C1 (en) * 2016-03-16 2022-03-30 Амаль Терапьютикс Са Combination of an immune checkpoint modulator and a complex containing a cell-penetrating peptide, a cargo molecule, and a tlr peptide agonist, for application in medicine
WO2017214575A1 (en) * 2016-06-10 2017-12-14 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2018005276A1 (en) * 2016-06-29 2018-01-04 The Johns Hopkins University Neoantigens as targets for immunotherapy
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
EP3523451A1 (en) * 2016-10-06 2019-08-14 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP2020507557A (en) 2016-12-01 2020-03-12 ナントミクス,エルエルシー Processing and presentation of tumor antigenicity
US11480572B2 (en) 2016-12-16 2022-10-25 Nantbio, Inc. Live cell imaging systems and methods to validate triggering of immune response
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
CA3050109A1 (en) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018146128A1 (en) * 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018170329A1 (en) * 2017-03-17 2018-09-20 Nantomics, Llc LIQUID BIOPSY FOR cfRNA
WO2018183928A1 (en) * 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
JP2020522479A (en) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ Methods for making personalized cancer vaccines
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
CA3076894A1 (en) * 2017-09-25 2019-03-28 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. Neoantigen identification using hotspots
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
JP7421474B2 (en) 2017-11-03 2024-01-24 ガーダント ヘルス, インコーポレイテッド Normalization of tumor gene mutation burden
EP3707272A4 (en) * 2017-11-09 2021-11-24 The Trustees of The University of Pennsylvania Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR20200093438A (en) * 2017-12-01 2020-08-05 일루미나, 인코포레이티드 Method and system for determining somatic mutant clonability
CN108009400B (en) * 2018-01-11 2018-07-06 至本医疗科技(上海)有限公司 Full-length genome Tumor mutations load forecasting method, equipment and storage medium
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
KR20210005646A (en) 2018-04-26 2021-01-14 아게누스 인코포레이티드 Heat shock protein-binding peptide composition and method for use thereof
CA3107983A1 (en) 2018-07-23 2020-01-30 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
WO2020047378A1 (en) 2018-08-31 2020-03-05 Guardant Health, Inc. Microsatellite instability detection in cell-free dna
CN109371005B (en) * 2018-11-12 2022-09-30 上海市东方医院(同济大学附属东方医院) HLA-0201 restrictive PADI4 epitope polypeptide and application thereof
CN113194995A (en) * 2018-12-12 2021-07-30 免疫医疗有限责任公司 Predicting overall survival of non-small cell lung cancer based on tumor mutation burden of blood
JP2022525487A (en) * 2019-04-05 2022-05-17 イルミナ インコーポレイテッド Quantitative score of HLA diversity
NL2024107B1 (en) * 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
CN111088349B (en) * 2020-02-14 2023-04-28 深圳市宝安区妇幼保健院 KIR3DL1 genotyping primer group and application thereof
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
WO2022217136A1 (en) * 2021-04-10 2022-10-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. A multiomic approach to modeling of gene regulatory networks in multiple myeloma
CA3227081A1 (en) 2021-08-24 2023-03-02 Irena RABE In vitro transcription technologies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US9222938B2 (en) * 2001-12-04 2015-12-29 Michael Tainsky Neoepitope detection of disease using protein arrays
CN101072578A (en) * 2004-10-29 2007-11-14 南加州大学 Combination cancer immunotherapy with co-stimulatory molecules
CA3197245A1 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer

Also Published As

Publication number Publication date
KR20160102314A (en) 2016-08-29
AU2014374020A1 (en) 2016-08-18
PH12016501329A1 (en) 2016-10-03
RU2707530C2 (en) 2019-11-27
CL2016001708A1 (en) 2017-03-17
EP3090066A2 (en) 2016-11-09
RU2016131207A (en) 2018-02-07
PE20161344A1 (en) 2016-12-23
RU2016131207A3 (en) 2018-06-22
SG11201605432RA (en) 2016-07-28
WO2015103037A2 (en) 2015-07-09
US20160326597A1 (en) 2016-11-10
BR112016015399A2 (en) 2017-10-24
JP2017504324A (en) 2017-02-09
CN106164289A (en) 2016-11-23
EP3090066A4 (en) 2017-08-30
CA2935214A1 (en) 2015-07-09
MX2016008771A (en) 2016-12-20
WO2015103037A3 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
PH12016501329A1 (en) Determinants of cancer response to immunotherapy
JOP20200192A1 (en) Anti-tigit antibodies
CY1122510T1 (en) ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017000116A (en) Il-15-based molecules and methods of use thereof.
MX2021013586A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use.
WO2016081947A3 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
WO2015116868A3 (en) Molecular profiling of immune modulators
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
EP4007984A4 (en) Self-sovereign identity systems and methods for identification documents
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX370807B (en) Antibodies binding axl.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MY191539A (en) Streptococcal vaccine
EP3209766A4 (en) Tissue sample processing system and associated methods
MX2015014190A (en) Covalently closed non-coding immunomodulatory dna construct.
FR3022664B1 (en) AUTHENTICATION METHOD AND SYSTEM
EP3191121A4 (en) Identification of immunologically protective neo-epitopes for the treatment of cancers
MA40636A (en) Methods of detecting prostate cancer
IL248080A0 (en) System and method of identifying sources associated with biological rhythm disorders
EP3234841A4 (en) Computer-implemented system and method for identifying similar patients
EP3157680A4 (en) Molecular analysis system and use thereof
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
PLOS Neglected Tropical Diseases Staff Correction: A Novel qPCR Assay for the Detection of African Animal Trypanosomosis in Trypanotolerant and Trypanosusceptible Cattle Breeds